Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.
- DOI
- 10.1093/ecco-jcc/jjae164
- Published
- 2025 Apr 4
- Container
- Journal of Crohn's & colitis
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/ecco-jcc/jjae164,
title = {Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.},
author = {Atreya R and Ferrante M and Panaccione R and Feagan B and Shchukina O and Jairath V and Rieder F and Hisamatsu T and Siegmund B and Kligys K and Song A and Zambrano J and Mallick M and Zhang Y and Armuzzi A and D'Haens G},
year = {2025},
journal = {Journal of Crohn's \& colitis},
doi = {10.1093/ecco-jcc/jjae164},
url = {https://doi.org/10.1093/ecco-jcc/jjae164}
}RIS
TY - JOUR TI - Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies. AU - Atreya R AU - Ferrante M AU - Panaccione R AU - Feagan B AU - Shchukina O AU - Jairath V AU - Rieder F AU - Hisamatsu T AU - Siegmund B AU - Kligys K AU - Song A AU - Zambrano J AU - Mallick M AU - Zhang Y AU - Armuzzi A AU - D'Haens G PY - 2025 JO - Journal of Crohn's & colitis DO - 10.1093/ecco-jcc/jjae164 UR - https://doi.org/10.1093/ecco-jcc/jjae164 ER -
APA
R, A., M, F., R, P., B, F., O, S., V, J., F, R., T, H., B, S., K, K., A, S., J, Z., M, M., Y, Z., A, A., & G, D. (2025). Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.. Journal of Crohn's & colitis. https://doi.org/10.1093/ecco-jcc/jjae164
Source records
- pubmed · retrieved 2026-09-26T17:12:42.735Z